Mounjaro vs Zepbound: Dosing Differences Between Two Tirzepatide Brands

Mounjaro and Zepbound are both manufactured by Eli Lilly and both contain tirzepatide as their active ingredient. The key difference is regulatory: Mounjaro was FDA-approved in May 2022 for the treatment of type 2 diabetes, while Zepbound received approval in November 2023 specifically for chronic weight management in adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related comorbidity.

This distinction matters primarily for insurance coverage and prescribing. The medication itself, its mechanism of action, and its administration are identical. Both are once-weekly subcutaneous injections delivered via single-dose prefilled pens.

Both Mounjaro and Zepbound are available in the same six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The escalation schedule is also identical. Treatment starts at 2.5 mg weekly for four weeks, then increases to 5 mg. From 5 mg onward, the dose may be increased by 2.5 mg increments every four weeks based on tolerability and clinical response.

The minimum maintenance dose for both brands is 5 mg weekly, and the maximum is 15 mg weekly. There is no difference in the titration protocol between the diabetes indication (Mounjaro) and the weight management indication (Zepbound). Providers follow the same gradual escalation to minimize gastrointestinal side effects like nausea and diarrhea.

Both brand-name products come as prefilled single-dose pens. Each pen contains one dose at a specific strength, and you select the pen that matches your current prescribed dose. There is no need to measure or calculate units -- you simply inject the entire contents of the pen.

Compounded tirzepatide, by contrast, is dispensed in multi-dose vials at concentrations like 5 mg/mL, 10 mg/mL, or 20 mg/mL. Patients draw their dose using a U-100 insulin syringe and must convert milligrams to syringe units using the formula: units = (dose in mg / concentration in mg/mL) x 100. This requires more precision but offers significant cost savings compared to brand-name pens.

The biggest practical difference between Mounjaro and Zepbound is insurance coverage. Most commercial insurance plans cover Mounjaro for type 2 diabetes, often with prior authorization. Coverage for Zepbound for weight management is less common, as many insurers still classify anti-obesity medications as elective or non-essential.

List prices are similar: Mounjaro is approximately $1,000 per month and Zepbound approximately $1,060 per month at retail. Eli Lilly offers manufacturer savings programs for both, which can reduce costs for commercially insured patients. For patients without coverage, compounded tirzepatide from licensed pharmacies is typically $300 to $500 per month, regardless of the brand-name indication.

Some patients receive a Mounjaro prescription even when their primary goal is weight loss, if they also have type 2 diabetes or prediabetes. This is a legitimate clinical decision, not off-label use, since Mounjaro is approved for glycemic control in patients who may also benefit from weight reduction.

If you have type 2 diabetes, Mounjaro is the FDA-approved option and more likely to be covered by your insurance. If your primary goal is weight management and you do not have diabetes, Zepbound is the indicated brand, though coverage may be limited.

In practice, many patients access tirzepatide through compounded formulations rather than either brand-name pen. Compounded tirzepatide delivers the same active ingredient at a fraction of the cost. The dosing math is slightly more involved since you measure from a vial, but a dosage calculator makes the conversion straightforward. Regardless of which form you use, the medication, dose escalation, and expected clinical outcomes are the same.